Decoy Therapeutics Inc. DCOY 深 沪
等待开盘 04-02 09:30:00 美东时间
6.32
-0.211
-3.22%
华盛通- 最 高6.89
- 今 开6.89
- 成交量 1.96万股
- 最 低 6.0655
- 昨 收 6.5306
- 总市值 589.78万
- 52周最高 415.80
- 市盈率 静 --
- 换手率 2.10%
- 52周最低 5.94
- 委 比 39.52%
- 总股本 93.32万
- 历史最高 533340.00
- 量 比 0.60
- 振 幅 12.63%
- 历史最低 6.0655
- 每 手 1
- 风险率 57.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Decoy Therapeutics shares are trading lower after the company announced a 1-for-12 reverse stock split.
Decoy Therapeutics shares are trading lower after the company announced a 1-for...
03-06 01:25
Decoy Therapeutics Announces 1‑For‑12 Reverse Stock Split Effective March 6
Decoy Therapeutics Inc. (NASDAQ:DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock
03-05 21:39
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conju...
03-05 21:30
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
- Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharm...
02-11 22:00
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Ladenburg Thalmann Initiates Coverage On Decoy Therapeutics with Buy Rating, Announces Price Target of $2.5
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Decoy Therapeutics (NASDAQ:DCOY) with a Buy rating and announces Price Target of $2.5.
01-23 20:29
Decoy Therapeutics Announces Funded Development Of Global Manufacturing Platform For Peptide‑Conjugate Antivirals Under Gates Foundation Access Agreement
Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP3ACT™ platform for low- and middle-income
01-13 21:20
Salarius Pharmaceuticals Updates Merger Agreement with Decoy Therapeutics Amid Market Changes
Salarius Pharmaceuticals Inc. announced a significant update to its merger agreement with Decoy Therapeutics Inc. On June 10, 2025, the company entered into a Second Amendment to the Merger Agreement,...
2025-06-11 20:39
